Skip to content
Screener

GeneDx Holdings WGS Q3 2025 earnings

Reported October 28, 2025 · Before market open

Revenue$116.7MMiss by $3.7M
EPS$0.49Beat by $0.21
Revenue estimate$120.5M
EPS estimate$0.28

Next report

Oct 27, 2026 (in a month)
Revenue estimate$123.0M
EPS estimate$0.07

Financials

Q3 2025

Income statement

See full
Revenue$116.7M+51.9%
Gross profit$84.5M+76.7%
Operating income-$3.3M+58.2%
Net income-$7.6M+8.1%
EPS (diluted)-$0.27+12.9%

Balance sheet

See full
Cash & equivalents$97.0M+64.7%
Total debt$52.8M-0.8%
Total equity$292.3M+42.9%
Total assets$493.9M+20.8%

Cash flow

See full
Operating cash flow$15.8M+459%
CapEx$6.2M+855%
Free cash flow$9.6M+290%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$3.09B+171%
Enterprise value$3.05B+168%
P/S7.7×+3.4×

Profitability

See full
Gross margin69.6%+10.2pp
FCF margin3.8%+2.1pp

Returns & leverage

See full
Debt / equity0.2×-0.1×
Current ratio2.7×+0.3×

FAQ

When did GeneDx Holdings report Q3 2025 earnings?
GeneDx Holdings (WGS) reported Q3 2025 earnings on October 28, 2025 before market open.
What were GeneDx Holdings's Q3 2025 revenue and EPS?
GeneDx Holdings reported revenue of $116.7M and eps of $0.49 for Q3 2025.
Did GeneDx Holdings beat estimates in Q3 2025?
Revenue missed the consensus estimate of $120.5M by $3.7M. EPS beat the consensus estimate of $0.28 by $0.21.
How did GeneDx Holdings's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 51.9% from $76.9M a year earlier and eps grew 1125.0% from $0.04.
Where can I find GeneDx Holdings's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001818331-25-000128) and the 10-Q periodic report (0001818331-25-000130) directly on SEC EDGAR. The filing index links above go to sec.gov.